Compare OWLT & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OWLT | VRCA |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | United States |
| Employees | 114 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.7M | 137.3M |
| IPO Year | N/A | 2018 |
| Metric | OWLT | VRCA |
|---|---|---|
| Price | $5.67 | $6.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $17.50 | $17.00 |
| AVG Volume (30 Days) | ★ 172.4K | 79.2K |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | $22.81 | N/A |
| Revenue Next Year | $20.45 | $94.44 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $4.19 | $0.49 |
| 52 Week High | $16.94 | $9.82 |
| Indicator | OWLT | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 51.80 | 45.63 |
| Support Level | $5.25 | $5.13 |
| Resistance Level | $6.22 | $6.40 |
| Average True Range (ATR) | 0.36 | 0.62 |
| MACD | 0.06 | -0.15 |
| Stochastic Oscillator | 55.92 | 21.68 |
Owlet Inc is engaged in providing a digital parenting platform that aims to give parents real-time data and insights to help parents feel more calm and confident. Its diversified portfolio of products includes Owlet Smart Sock, the first baby monitor to track an infant's oxygen levels, heart rate, and sleep trends; the Owlet Cam, which turns any smartphone into a baby monitor with high-definition clarity; the Owlet Monitor Duo, which offers the intelligence of the Owlet Smart Sock paired with the Owlet Cam; and Owlet Dream Lab, an interactive online program designed to be a parent's guide to building healthy sleep habits for their infants.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.